scholarly journals A retrospective analysis of the therapeutic effects of 0.01% atropine on axial length growth in children in a real-life clinical setting

2021 ◽  
Author(s):  
Hakan Kaymak ◽  
Birte Graff ◽  
Frank Schaeffel ◽  
Achim Langenbucher ◽  
Berthold Seitz ◽  
...  
Keyword(s):  
Retrospective Analysis ◽  
Clinical Setting ◽  
Axial Length ◽  
Therapeutic Effects ◽  
Eye Drops ◽  
Initial Visit ◽  
Myopia Progression ◽  
Beneficial Effects ◽  
Length Growth ◽  
Routine Clinical Setting

Abstract Background Several randomized controlled studies have demonstrated the beneficial effects of 0.01% atropine eye drops on myopia progression in children. However, treatment effects may be different in a routine clinical setting. We performed a retrospective analysis of our clinical data from children to investigate the effect of 0.01% atropine eye drops on myopia progression in a routine clinical setting. Methods Atropine-treated children were asked to instill one drop of 0.01% atropine in each eye every evening at 5 days a week. Myopic children who did not undergo atropine treatment served as controls. Objective refraction and ocular biometry of 80 atropine-treated and 103 untreated children at initial visit and 1 year later were retrospectively analyzed. Results Myopic refractions in the treated and untreated children at initial visit ranged from −0.625 to −15.25 D (−4.21 ± 2.90 D) and from −0.125 to −9.375 D (−2.92 ± 1.77 D), respectively. Ages at initial visit ranged from 3.2 to 15.5 years (10.1 ± 2.7 years) in the treated and from 3.4 to 15.5 years (11.2 ± 3.0 years) in untreated children. Two-factor ANOVA for age and atropine effects on axial length growth confirmed that axial length growth rates declined with age (p<0.0001) and revealed a significant inhibitory effect of atropine on axial length growth (p<0.0015). The atropine effect on axial length growth averaged to 0.08 mm (28%) inhibition per year. Effects on refraction were not statistically significant. Conclusion The observed atropine effects were not very distinctive: Statistical analysis confirmed that atropine reduced axial length growth, but to an extent of minor clinical relevance. It was also shown that beneficial effects of 0.01% atropine may not be obvious in each single case, which should be communicated with parents and resident ophthalmologists.

Topical atropine in retarding myopia progression and axial length growth in children with myopia

2020 ◽  
Vol 13 (4) ◽  
pp. 111-114
Author(s):  
Abdur Rahman Mohammad Alam ◽  
Md. Sanwar Hossain ◽  
Md. Shafiqul Islam
Keyword(s):  
Axial Length ◽  
Control Group ◽  
Refractive Errors ◽  
Spherical Equivalent ◽  
Myopia Progression ◽  
Length Growth ◽  
Significant Difference ◽  
The Mean ◽  
And Control

This study was conducted to observe the effect of atropine in retarding myopia progression and axial length growth in 36 myopic children (atropine group, 24; control, 12). The initial spherical equivalent of the atropine group and control group was -3.0 ± 1.6 dioptre and -3.5 ± 1.6 dioptre respectively. At the 12th month in atropine group, it was -2.9 ± 2.6 dioptre and -4.6 ± 1.9 dioptre in the control group. The power of the atropine group reduced but rose in the control group after 12 months. There was a statistically significant difference in final refractive errors between the two groups (p<0.05). The initial axial length of the atropine group and control group was 24.3± 1.0 mm and 24.6 ± 1.1 mm respectively. In 12th month, the changes in axial length in the two groups was insignificant. However, the mean axial length progression at 12 months of the atropine group was -0.1 ± 0.1 mm and it was lower than the control group which was -0.2 ± 0.2 mm, and this was statistically significant (p<0.05). In conclusion, topical atropine (0.01%) retarded myopia progre-ssion and axial length growth in myopic children.    

scholarly journals Predictive factors associated with axial length growth and myopia progression in orthokeratology

PLoS ONE ◽  
2019 ◽  
Vol 14 (6) ◽  
pp. e0218140 ◽  
Author(s):  
Jaeryung Kim ◽  
Dong Hui Lim ◽  
Sun Hyup Han ◽  
Tae-Young Chung
Keyword(s):  
Predictive Factors ◽  
Axial Length ◽  
Myopia Progression ◽  
Factors Associated ◽  
Length Growth

scholarly journals Use baseline axial length measurements in myopic patients to predict the control of myopia with and without atropine 0.01%

PLoS ONE ◽  
2021 ◽  
Vol 16 (7) ◽  
pp. e0254061
Author(s):  
Loreto V. T. Rose ◽  
Angela M. Schulz ◽  
Stuart L. Graham
Keyword(s):  
Growth Rate ◽  
Axial Length ◽  
Rate Of Change ◽  
Spherical Equivalent ◽  
Myopia Progression ◽  
Paired Difference ◽  
Length Growth ◽  
Slow Progressors ◽  
Pre Treatment ◽  
Change In Mean

Purpose Identifying axial length growth rate as an indicator of fast progression before initiating atropine 0.01% for myopia progression in children. Method From baseline, axial length growth over six months was measured prospectively. Subjects were then initiated on atropine 0.01% if axial length growth was greater than 0.1mm per 6 months (fast progressors), axial length and spherical equivalent change measurements recorded every six months. The rate of change was compared to the baseline pre-treatment rate. If axial length change was below the threshold, subjects received monitoring only. Results 73 subjects were identified as fast progressors and commenced atropine 0.01%, (mean baseline refraction of OD -2.9±1.6, OS -2.9±1.8 and a mean baseline axial length OD 24.62 ± 1.00 mm, OS 24.53 ± 0.99 mm). At six months, the mean paired difference of axial length growth rate was significantly reduced by 50% of baseline (all 73 subjects, p<0.05). 53 subjects followed to 12 months, and 12 to 24 months maintained a reduced growth rate. Change in mean spherical equivalent was significantly reduced compared to pre-treatment refractive error (mean paired difference p<0.05) and at each subsequent visit. 91 children were slow progressors and remained untreated. Their axial length growth rate did not change significantly out to 24 months. Spherical equivalent changed less than -0.5D annually in this group. Conclusion Identifying fast progressors before treatment initiation demonstrated a strong treatment effect with atropine 0.01% reducing their individual rate of myopia progression by 50%. Another large group of myopic children, slow progressors, continued without medical intervention. A baseline axial length growth rate is proposed as a guideline to identify fast progressors who are more likely to benefit from atropine 0.01%.

scholarly journals Myopia Progression Risk: Seasonal and Lifestyle Variations in Axial Length Growth in Czech Children

2018 ◽  
Vol 2018 ◽  
pp. 1-5 ◽  
Author(s):  
Stepan Rusnak ◽  
Vaclav Salcman ◽  
Lenka Hecova ◽  
Zdenek Kasl
Keyword(s):  
Risk Factors ◽  
Potential Risk ◽  
Axial Length ◽  
Winter Season ◽  
Myopia Progression ◽  
Length Growth ◽  
Significant Difference ◽  
Potential Risk Factors ◽  
Daylight Exposure ◽  
Near Work

The growth in the prevalence of myopia leads to the growth of socioeconomic stress in society. It is important to detect any potential risk factors leading to myopia onset and progression. Among the potential risk factors, the lack of natural daylight exposure and the lack of the physical activity together with excess of near-work activities in children are the most prevalent. In the study, the axial length growth depending on the season and the type of behaviour was measured. The assessment was performed in 12-year-old children, 398 eyes of whom were included and measured during the winter and summer period. The children were categorized by the amount of time spent on near-work, physical, and outdoor activity. Results. Statistically significantly higher (p<0.0001) axial length growth was observed during the winter period. Statistically significantly (p<0.0001) more frequently, the eyeball growth has been proved during the winter season. According to the way of spending leisure time, no statistically significant difference was reported within the individual subgroups in the development of the eyeball length during the observed period. However, statistically significant differences were ascertained in the eyeball initial length within various groups. Conclusion. The lack of daylight exposure may lead to myopia progression.

scholarly journals The Treatment Zone Size and Its Decentration Influence Axial Length Grow in Children With Orthokeratology Treatment

2021 ◽  
Author(s):  
Weiping Lin ◽  
Na Li ◽  
Tianpu Gu ◽  
Chunyu Tang ◽  
Bei Du ◽  
...  
Keyword(s):  
Axial Length ◽  
Corneal Topography ◽  
Spherical Equivalent ◽  
Zone Size ◽  
Inclusion Criteria ◽  
Myopia Progression ◽  
Treatment Zone ◽  
Length Growth ◽  
Lens Wear

Abstract Background: To investigate whether the treatment zone size (TZS) and treatment zone decentration (TZD) will affect the axial length growth in myopic children undergoing orthokeratology treatment.Methods: A self-controlled retrospective study was conducted on 352 children who met the inclusion criteria. Axial length was measured before and at 12 months after the initial lens wear. Corneal topography was measured at baseline and at each follow-up after lens wear. The Corneal topography obtained from the 12-month visit was used to quantify TZS and TZD for each subject. Cycloplegic refraction was required for all subjects before fitting the orthokeratology lenses. Results: Axial length growth was significantly associated with age, baseline spherical equivalent (SE), TZS, and TZD with univariate linear regression. In groups with both small and large TZS, axial length growth was significantly decreased with large TZD (both P < 0.001). In groups with both small and large TZD, axial length growth was significantly decreased with small TZS (P = 0.027 for small TZD, P = 0.011 for large TZD). Age, SE, and TZD were significantly associated with axial length growth in multiple regression (all P < 0.001). Conclusion: Relatively smaller TZS and larger TZD may be beneficial in slowing myopia progression in children with orthokeratology treatment.

HBOT Application at Cases of Gingival Inflammation

2019 ◽  
Author(s):  
Ilma Robo
Keyword(s):  
Root Resorption ◽  
Periodontal Diseases ◽  
Therapeutic Effects ◽  
Clinical Effects ◽  
Gingival Inflammation ◽  
Beneficial Effects ◽  
New Therapeutic Approaches ◽  
Short Period ◽  
Mechanical Therapy ◽  
The Impact

The treatment of periodontal diseases, mainly of their origin, with the most common clinical manifestation in form of gingival inflammation, is manifold and powerful, including: mechanical therapy, antibiotic, antiseptic and various approaches to treatment, which are recommended to be used within a short period of time. New therapeutic approaches have been proven as alternative treatment to conventional therapy, or in combination with conventional therapies, to reduce the number of periodontopathic pathogens in gingival sulcus. HBOT has a detrimental effect on periodontal microorganisms, as well as beneficial effects on the healing of periodontal tissue, increasing oxygen pressure in gingival pockets. Our study is aimed at reviewing the current published literature on hyperbaric oxygen therapy and focuses on role of HBOT as a therapeutic measure for the individual with periodontal disease in general and for the impact on the recovery of gingival inflammation. HBOT and periodontal treatment together, reduce up to 99% of the gram-negative anaerobic load of subgingival flora. HBOT, significantly reduces subgingival anaerobic flora. Clinical effects in 2-year follow-up of treated patients are sensitive. Reduction of gingival hemorrhage indexes, depth of peritoneum, plaque index, occurs in cases of combination of HBOT and detraction. Reduced load persists up to 2 months after therapy. The significant increase in connective tissue removal starts at the end of 2nd week, to achieve the maximum in week 3-6 of application. HBOT used for re-implantation, stimulates the healing of periodontal membrane, pulp, prevents root resorption, healing of periodontal lining tissues. HBOT, significantly reduces the hemorrhage index with 1.2 value difference, 0.7mm probe depth, reduces gingival fluid by 2. HGH exposure is increased by gingival blood flow, with a difference of 2 in measured value. The therapeutic effects of HBOT in the value of the evaluation index can be saved up to 1-year post treatment.

Yogic Intervention in Sexual Dysfunction - A Review

2017 ◽  
Vol 2 (4) ◽  
Author(s):  
Rakshith K. R. ◽  
Shivakumar . ◽  
Kaushal Sinha ◽  
Vijeth Kumar L. A.
Keyword(s):  
Psychological Functioning ◽  
Empirical Studies ◽  
Empirical Literature ◽  
Future Research ◽  
Therapeutic Effects ◽  
Yoga Therapy ◽  
Cognitive Component ◽  
Beneficial Effects ◽  
Breathing Exercises ◽  
The Mind

Yoga is an ancient practice with Eastern roots that involves both physical postures (Asanas) and breathing techniques (Pranayamas). Yoga therapy for male sexual problems can effectively be treated through Yoga therapy, particularly with the help of Yoga poses and breathing exercises, Yoga has proven itself highly very effective in the treatment of a number of incurable and sometimes terminable diseases. Then again, Yoga's therapeutic effects are just a spin-off and supplementary. Yoga which has proved to be very effective in the treatment of many impossible and incurable diseases, the therapeutic effect of Yoga is only a by product and incidental. Problems related to sex can very well be handled with Yoga as most often these problems are more related to the mind than body. Either they are caused by lack of confidence or stress or fatigue or fear and very few times some physical cause is there. There is also a cognitive component focusing on meditation and concentration, which aids in achieving the goal of union between the self and the spiritual. Although numerous empirical studies have found a beneficial effect of Yoga on different aspects of physical and psychological functioning, claims of Yoga's beneficial effects on sexuality derive from a rich but no empirical literature. The goal of this article is to review the philosophy and forms of Yoga, to review the no empirical and (limited) empirical literatures linking Yoga with enhanced sexuality, and to propose some future research avenues focusing on Yoga as a treatment for sexual disorder.

scholarly journals Accuracy of guided biopsy of the jawbone in a clinical setting: A retrospective analysis

2021 ◽  
Author(s):  
Martin Lotz ◽  
Caterina Schumacher ◽  
Bernd Stadlinger ◽  
Kristian Ikenberg ◽  
Martin Rücker ◽  
...  
Keyword(s):  
Retrospective Analysis ◽  
Clinical Setting ◽  
Guided Biopsy

scholarly journals The Effect of Long-Term Low-Dose Atropine on Refractive Progression in Myopic Australian School Children

2021 ◽  
Vol 10 (7) ◽  
pp. 1444
Author(s):  
William Myles ◽  
Catherine Dunlop ◽  
Sally A. McFadden
Keyword(s):  
Low Dose ◽  
High Dose ◽  
Eye Drops ◽  
Myopia Progression ◽  
At Risk Children ◽  
Slow Group ◽  
Blue Eyes ◽  
Global Population ◽  
Axial Growth

Myopia will affect half the global population by 2050 and is a leading cause of vision impairment. High-dose atropine slows myopia progression but with undesirable side-effects. Low-dose atropine is an alternative. We report the effects of 0.01% or 0.005% atropine eye drops on myopia progression in 13 Australian children aged between 2 and 18 years and observed for 2 years without and up to 5 years (mean 2.8 years) with treatment. Prior to treatment, myopia progression was either ‘slow’ (more positive than −0.5D/year; mean −0.19D/year) or ‘fast’ (more negative than −0.5D/year; mean −1.01D/year). Atropine reduced myopic progression rates (slow: −0.07D/year, fast: −0.25D/year, combined: before: −0.74, during: −0.18D/year, p = 0.03). Rebound occurred in 3/4 eyes that ceased atropine. Atropine halved axial growth in the ‘Slow’ group relative to an age-matched model of untreated myopes (0.098 vs. 0.196mm/year, p < 0.001) but was double that in emmetropes (0.051mm/year, p < 0.01). Atropine did not slow axial growth in ‘fast’ progressors compared to the age-matched untreated myope model (0.265 vs. 0.245mm/year, p = 0.754, Power = 0.8). Adverse effects (69% of patients) included dilated pupils (6/13) more common in children with blue eyes (5/7, p = 0.04). Low-dose atropine could not remove initial myopia offsets suggesting treatment should commence in at-risk children as young as possible.

Sign in / Sign up

Export Citation Format

Share Document